Late-onset distal myopathy, Markesbery-Griggs type
leyt-ON-set DIS-tuhl my-OP-uh-thee, MARK-es-berry-GRIGGS type
Also known as: ZASP-related myofibrillar myopathy, distal myopathy with ZASP mutation
At a Glance
What is Late-onset distal myopathy, Markesbery-Griggs type?
Late-onset distal myopathy, Markesbery-Griggs type, is a rare genetic disorder affecting muscle function. It primarily impacts the muscles of the lower legs and feet, leading to weakness and atrophy. The condition is caused by mutations in the ZASP gene, which plays a critical role in muscle fiber structure. Symptoms usually begin in adulthood and progress slowly over time. Early symptoms include difficulty walking and frequent falls, while later stages may involve more severe muscle weakness. Early diagnosis is crucial to manage symptoms and slow progression. The disorder can significantly impact family life, as affected individuals may require assistance with daily activities. Prognosis varies, but many individuals maintain mobility with appropriate interventions. Daily life can be challenging, with adaptations needed for mobility and self-care. The condition does not typically affect life expectancy, but quality of life may be impacted. Supportive therapies, including physical therapy, can help manage symptoms. Genetic counseling is recommended for affected families to understand inheritance patterns.
Medical Definition
Late-onset distal myopathy, Markesbery-Griggs type, is characterized by progressive muscle weakness due to mutations in the ZASP gene. Pathologically, it involves myofibrillar disorganization and Z-line streaming in muscle fibers. Histological findings include the presence of protein aggregates and rimmed vacuoles within muscle tissue. It is classified under distal myopathies, specifically those affecting the lower extremities. Epidemiologically, it is a rare condition with a prevalence of approximately 1 in 1,000,000 individuals. The disease course is typically slow and progressive, with symptoms manifesting in adulthood and gradually worsening over time.
Late-onset distal myopathy, Markesbery-Griggs type Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Muscle weakness in late-onset distal myopathy, Markesbery-Griggs type, typically manifests in the distal muscles of the lower limbs, leading to difficulty in walking and balance. This weakness is caused by the degeneration of muscle fibers due to mutations affecting the ZASP protein, which is crucial for muscle integrity. Over time, the weakness progresses, potentially leading to significant mobility impairment. Daily life is affected as patients may require assistive devices for walking, and physical therapy can help maintain muscle function.
Muscle atrophy is characterized by a noticeable decrease in muscle mass, particularly in the lower legs. It results from the chronic degeneration of muscle fibers and insufficient muscle regeneration. As the condition progresses, muscle atrophy becomes more pronounced, leading to reduced strength and endurance. Patients may experience difficulties in performing daily activities, and interventions such as resistance exercises can help slow the progression.
Foot drop is a condition where the patient is unable to lift the front part of the foot, causing a dragging effect when walking. This occurs due to weakness in the muscles responsible for dorsiflexion, often linked to nerve and muscle damage. Over time, foot drop can lead to compensatory gait patterns, increasing the risk of falls. Ankle-foot orthoses and physical therapy are commonly used to manage this symptom and improve mobility.
Common
Gait abnormalities are often observed as patients struggle with balance and coordination due to muscle weakness. These abnormalities stem from the compromised function of distal muscles, affecting the patient's ability to walk smoothly. As the condition advances, gait abnormalities may worsen, leading to increased fatigue and risk of falls. Rehabilitation strategies and assistive devices can help improve gait and reduce fall risk.
Muscle cramps are sudden, involuntary contractions of muscles, often occurring in the legs. They are thought to be caused by the instability of muscle fibers and altered neuromuscular control. Over time, cramps can become more frequent and painful, disrupting sleep and daily activities. Stretching exercises and hydration are recommended to alleviate and prevent cramps.
Fatigue is a common symptom, presenting as a persistent feeling of tiredness and lack of energy. It is primarily due to the increased effort required to perform activities with weakened muscles. As the disease progresses, fatigue can become more debilitating, affecting work and social life. Energy conservation techniques and adequate rest are essential in managing fatigue.
Less Common
Respiratory muscle weakness may occur in some patients, leading to difficulties in breathing and reduced lung capacity. This weakness is due to the involvement of respiratory muscles in the degenerative process. Over time, respiratory function may decline, necessitating interventions such as respiratory therapy. Monitoring and supportive care are crucial to manage respiratory complications.
Cardiac involvement can manifest as arrhythmias or cardiomyopathy in a subset of patients. This occurs due to the potential impact of ZASP mutations on cardiac muscle fibers. As the condition progresses, cardiac symptoms may become more pronounced, requiring medical intervention. Regular cardiac evaluations and management of symptoms are essential for maintaining heart health.
What Causes Late-onset distal myopathy, Markesbery-Griggs type?
Late-onset distal myopathy, Markesbery-Griggs type, is primarily caused by mutations in the ZASP gene, located on chromosome 10q22.3. The ZASP gene encodes the Z-band alternatively spliced PDZ-motif protein, which plays a crucial role in maintaining the structural integrity of the Z-disc in muscle fibers. Mutations in the PDZ-like motif of ZASP, such as Ala147Thr, disrupt the protein's ability to bind to other structural proteins, leading to compromised Z-disc assembly. This disruption results in the accumulation of misfolded proteins and myofibrillar disarray within the muscle cells. Consequently, the cellular architecture is destabilized, impairing muscle contraction and leading to muscle fiber degeneration. The ensuing muscle damage triggers an inflammatory response, which may involve the activation of immune cells and the release of pro-inflammatory cytokines. Over time, chronic inflammation can exacerbate muscle damage and contribute to the degeneration of surrounding tissues. In some cases, neuroinflammation may also play a role, although its exact contribution to disease progression is not fully understood. The specific pattern of muscle weakness, typically affecting distal muscles of the lower limbs, is thought to be due to the selective vulnerability of these muscle groups to the structural defects caused by ZASP mutations. Variability in disease severity among patients may be influenced by additional genetic factors, environmental influences, or differences in the immune response. The degeneration of muscle tissue may also affect the surrounding connective tissue and lead to secondary changes in muscle function. In advanced stages, the disease can lead to significant disability due to the progressive loss of muscle strength and function. Understanding the precise molecular mechanisms underlying these processes remains an area of active research.
How is Late-onset distal myopathy, Markesbery-Griggs type Diagnosed?
Typical age of diagnosis: Late-onset distal myopathy, Markesbery-Griggs type, is typically diagnosed in adulthood, often between the ages of 30 and 50, when patients present with progressive muscle weakness predominantly in the distal muscles of the legs.
The clinician looks for signs of muscle weakness, particularly in the distal muscles of the legs. A detailed family history is important to identify any hereditary patterns. Physical examination may reveal muscle atrophy and weakness in the lower limbs. This step helps to differentiate distal myopathy from other neuromuscular disorders.
Magnetic Resonance Imaging (MRI) of the lower limbs is the preferred modality. It may show selective muscle involvement with fatty infiltration and muscle atrophy. These findings can confirm the diagnosis of distal myopathy and exclude other conditions like peripheral neuropathy. MRI helps to visualize the pattern of muscle involvement, which is characteristic of this condition.
Serum creatine kinase (CK) levels are often measured, as they may be mildly elevated. Muscle biopsy may be performed to look for myopathic changes and protein aggregates. Abnormal results such as the presence of Z-band streaming or myofibrillar disorganization guide further genetic testing. These tests help to rule out inflammatory or metabolic myopathies.
Genetic testing focuses on sequencing the ZASP (LDB3) gene. Mutations such as Ala147Thr in the PDZ-like motif are commonly found. The presence of these mutations confirms the diagnosis of ZASP-related myopathy. Genetic results are crucial for family counseling and assessing the risk for other family members.
Late-onset distal myopathy, Markesbery-Griggs type Treatment Options
Corticosteroids are sometimes used to manage myopathy symptoms. They work by reducing inflammation and modulating immune response. Prednisone is a commonly used corticosteroid in this context. Clinical evidence for efficacy is limited, and benefits are variable. Potential side effects include weight gain, osteoporosis, and increased infection risk.
Physical therapy focuses on specific strengthening exercises for affected muscles. The goal is to maintain muscle function and delay progression of weakness. Sessions are typically recommended 2-3 times a week for optimal results. Measurable outcomes include improved muscle strength and endurance. Long-term benefits include enhanced mobility and quality of life.
Surgery may be indicated for severe foot drop to improve gait. The procedure involves transferring tendons from stronger muscles to compensate for weakened ones. Expected benefits include improved ambulation and reduced risk of falls. Surgical risks include infection and nerve damage. Post-operative care involves rehabilitation and gradual return to activity.
The care team typically includes neurologists, physiotherapists, and occupational therapists. Interventions focus on optimizing function and managing symptoms. Psychosocial support strategies include counseling and support groups. Family education is essential for understanding disease progression and care needs. Long-term monitoring involves regular follow-up to adjust care plans as needed.
When to See a Doctor for Late-onset distal myopathy, Markesbery-Griggs type
- Sudden difficulty breathing — this could indicate respiratory muscle involvement and requires immediate medical attention.
- Severe muscle weakness — if the weakness rapidly worsens, it may signal a critical progression of the disease.
- Acute chest pain — this could be a sign of cardiac involvement, which is a medical emergency.
- Progressive muscle weakness — this indicates disease progression and should prompt a consultation with a neurologist.
- Frequent falls — may suggest worsening muscle control and balance, requiring medical evaluation.
- Persistent fatigue — could indicate muscle wasting or other complications, warranting further investigation.
- Mild muscle cramps — monitor for frequency and intensity at home, and report if they worsen.
- Occasional muscle stiffness — keep track of when it occurs and any potential triggers.
Late-onset distal myopathy, Markesbery-Griggs type — Frequently Asked Questions
Is this condition hereditary?
Late-onset distal myopathy, Markesbery-Griggs type, is inherited in an autosomal dominant pattern. This means there is a 50% chance of passing the condition to children. De novo mutations can occur, meaning the mutation can appear for the first time in an individual. Carriers of the mutation will likely develop symptoms. Genetic counseling is recommended for affected individuals and their families.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the age of onset and severity of symptoms. Early diagnosis and management of symptoms can improve outcomes. Respiratory or cardiac complications are common causes of mortality. Treatment can help manage symptoms but may not significantly extend life expectancy. Patients should have realistic expectations and focus on quality of life improvements.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, genetic testing, and muscle biopsy. The time from first symptoms to diagnosis can vary, often taking several months to years. Neurologists and geneticists are commonly consulted. Delayed diagnosis may occur due to the rarity of the condition and overlapping symptoms with other myopathies. Genetic testing confirming a mutation in the ZASP gene finally confirms the diagnosis.
Are there any new treatments or clinical trials available?
Current research is exploring gene therapy and novel pharmacological approaches. ClinicalTrials.gov is a resource for finding ongoing trials related to this condition. Patients should discuss trial participation with their doctor, considering potential benefits and risks. New treatments may take several years to become widely available. Staying informed about research developments is crucial for accessing new therapies.
How does this condition affect daily life and activities?
The condition can significantly impact mobility, requiring assistive devices for walking. Educational and occupational adjustments may be necessary due to physical limitations. Social and emotional challenges include coping with chronic illness and potential isolation. Family members may face increased caregiving responsibilities. Supportive therapies and adaptive equipment can help maintain independence and improve quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.A novel mutation in the PDZ-like motif of ZASP causes distal ZASP-related myofibrillar myopathy.
Zheng J, Chen S, Chen Y et al. · Neuropathology · 2017 · PMID: 27546599
- 2.[Myofibrillary myopathy due to the ZASP mutation Ala147Thr : two cases with exclusively distal leg involvement].
Kraya T, Kress W, Stoevesant D et al. · Nervenarzt · 2013 · PMID: 23263837
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-15